Pfizer stock at EUR 27.49, up 1.14% premarket
Published on 11/05/2026 at 08:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPfizer outlook points to product momentum
- Pfizer raised its 2026 revenue outlook to USD 62.0 billion to USD 64.0 billion after third-quarter performance exceeded expectations.
- Newly launched and acquired products generated USD 3.8 billion and grew 32 percent operationally in the quarter.
- Cecile Guegan became chief financial officer on November 1, 2026.
Pfizer stock traded at 27.49 euros on Lang & Schwarz at 08:56 CET on Thursday, November 5, 2026, 1.14 percent above the Xetra close of Wednesday, November 4, 2026 at 27.18 euros.
Pfizer's third-quarter performance provides the latest business backdrop for the premarket indication. The company reported revenue of USD 16.58 billion and said newly launched and acquired products generated USD 3.8 billion, with operational growth of 32 percent.
Pfizer lifted its 2026 revenue forecast to USD 62.0 billion to USD 64.0 billion from a previous range of USD 60.5 billion to USD 62.5 billion. The company also raised its adjusted diluted earnings-per-share outlook to USD 2.95 to USD 3.05. The details are set out in Pfizer's third-quarter update.
Management said growth from newer products is helping offset continued weakness in COVID-19 product sales. Pfizer also appointed Cecile Guegan chief financial officer and executive vice president effective November 1, 2026. Investors can follow the real-time quote of Pfizer stock during the session.
The broader U.S. market backdrop is the S&P 500.
More company developments and market analysis are available in More news and analyses on Pfizer stock.
